A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized，multicenter, open-label Phase III, clinical study to confirm the
efficacy and safety of SKLB1028 in patients with relapsed or refractory(R/R) FLT3-Mutated
Acute Myeloid Leukemia（AML）compared to salvage chemotherapy.